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Immunotherapeutic strategies targeting the rare leukemic stem cell com-partment might provide salvage to the high relapse rates currentlyobserved in acute myeloid leukemia (AML). We applied gene expression
profiling for comparison of leukemic blasts and leukemic stem cells with
their normal counterparts. Here, we show that the T-cell receptor γ chain
alternate reading frame protein (TARP) is over-expressed in de novo pediatric
(n=13) and adult (n=17) AML sorted leukemic stem cells and blasts com-
pared to hematopoietic stem cells and normal myeloblasts (15 healthy con-
trols). Moreover, TARP expression was significantly associated with a fms-
like tyrosine kinase receptor-3 internal tandem duplication in pediatric
AML. TARP overexpression was confirmed in AML cell lines (n=9), and
was found to be absent in B-cell acute lymphocytic leukemia (n=5) and
chronic myeloid leukemia (n=1). Sequencing revealed that both a classical
TARP transcript, as described in breast and prostate adenocarcinoma, and
an AML-specific alternative TARP transcript, were present. Protein expres-
sion levels mostly matched transcript levels. TARP was shown to reside in
the cytoplasmic compartment and showed sporadic endoplasmic reticulum
co-localization. TARP-T-cell receptor engineered cytotoxic T-cells in vitro
killed AML cell lines and patient leukemic cells co-expressing TARP and
HLA-A*0201. In conclusion, TARP qualifies as a relevant target for
immunotherapeutic T-cell therapy in AML.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy,
accounting for 80% of adult1-4 and 20% of pediatric5-7 leukemia. Despite initial clin-
ical remission rates of 60-90%,2,5,6 patients exhibit a high relapse risk and therapy-
related mortality, resulting in a 5-year overall survival of 30% in adult AML1,3 and
65-70% in pediatric AML (pedAML).5,8 Especially the prognosis of patients with
fms-like tyrosine kinase receptor-3 internal tandem duplications (FLT3-ITD)
remains extremely poor.2,8,9 The high relapse rate is thought to arise from a
chemotherapy-resistant cell fraction with unlimited self-renewal capacities,
TARP is an immunotherapeutic target in
acute myeloid leukemia expressed in the
leukemic stem cell compartment
Barbara Depreter,1,2 Karin E. Weening,2,3 Karl Vandepoele,2,4 Magnus Essand,5
Barbara De Moerloose,1,2,6 Maria Themeli,7 Jacqueline Cloos,7
Diana Hanekamp,7 Ine Moors,8 Inge D’hont,6 Barbara Denys,2,4
Anne Uyttebroeck,9 An Van Damme,10 Laurence Dedeken,11
Sylvia Snauwaert,12 Glenn Goetgeluk,3 Stijn De Munter,2,3 Tessa Kerre,2,8
Bart Vandekerckhove,2,3 Tim Lammens1,2* and Jan Philippé2,3,4* 
1Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium;
2Cancer Research Institute Ghent, Ghent University, Ghent, Belgium; 3Department of
Diagnostic Sciences, Ghent University, Ghent, Belgium; 4Department of Laboratory
Medicine, Ghent University Hospital, Ghent, Belgium; 5Science for Life Laboratory,
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala,
Sweden; 6Department of Pediatric Hematology-Oncology and Stem Cell Transplantation,
Ghent University Hospital, Ghent, Belgium; 7Department of Hematology, VU University
Medical Center, Amsterdam, the Netherlands; 8Department of Hematology, Ghent
University Hospital, Ghent, Belgium; 9Department of Pediatrics, University Hospital
Gasthuisberg, Louvain, Belgium; 10Department of Pediatric Hematology Oncology,
University Hospital Saint-Luc, Brussels, Belgium; 11Department of Pediatric Hematology
Oncology, Queen Fabiola Children's University Hospital, Brussels, Belgium and
12Department of Hematology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium
*JP and TL contributed equally to this work as co-senior authors.
ABSTRACT
denominated as leukemic stem cells (LSC).4,10-14 In CD34+
AML, stem cell characteristics were shown to be present
in all four CD34/CD38 phenotypic compartments, though
the CD34+CD38– fraction was the  most LSC-enriched.15
Moreover, a high LSC load at diagnosis was shown to be
a significant adverse prognostic factor.16-19 Unfortunately,
current chemotherapeutic regimens were shown to per-
form inadequate towards LSC eradication14 and they
induce important toxicity.5,6,20 Also hematopoietic stem
cell transplantation, performed in high-risk (HR) patients
or as salvage therapy, carries a high mortality and morbid-
ity risk,2,5 highlighting the need for alternative treatments.
Thus, identifying LSC aberrations is crucial to tackle the
high relapse rate and to develop therapeutic targeting
strategies for LSC elimination, while ensuring salvage of
normal hematopoietic stem cells (HSC). 
Targeted therapy has led to remarkable progress in the
survival rates of multiple cancers. The introduction of
tyrosine kinase inhibitors in the treatment of chronic
myeloid leukemia (CML) accomplished a major break-
through, and CD19-directed chimeric antigen receptor
(CAR) therapy has led to an enormous improvement in
survival in relapsed/refractory pediatric ALL.21,22 These
successes paved the way for the exploration of the clinical
applicability of targeting antibodies and CAR- or T-cell
receptor (TCR)-transgenic cytotoxic T cells (CTL) in
AML.2,23-28 Although an increasing number of LSC-specific
membrane markers have been identified over recent
years,18,23,29,30 only a few reports address the molecular
abnormalities of LSC compared to HSC,15,31-37 especially in
pedAML. 
Here, we identified the T-cell receptor (TCR)γ chain
alternate reading frame protein (TARP) as an AML-specific
target, expressed in the LSC and blasts of pediatric and
adult AML, while absent in their normal counterparts.
TARP transcript expression was associated with FLT3-ITD
in pedAML. In addition, we provide in vitro evidence that
TARP may serve as a novel immunotherapeutic target in
AML for TARP-TCR engineered CTL.
Methods
Patients 
We retrospectively selected diagnostic material from 13
pedAML and 17 adult AML patients based on the sample avail-
ability, LSC load, CD34 positivity, FLT3 mutational status, and
HLA-status (Table 1 and Online Supplementary Table S1). At diag-
nosis, mononuclear cells (MNC) were isolated from bone marrow
(BM) or peripheral blood (PB) by Ficoll density gradient (Axis-
shield) and cryopreserved in 90% fetal calf serum (FCS) and 10%
dimethylsulfoxide (DMSO). Samples were thawed, followed by
30 minutes (min)  incubation at room temperature (RT) in 20 mL
RPMI with 20% FCS, 200 mL DNase I (1 mg/mL, grade II bovine
pancreas), and 200 mL MgCl2 (1 M) (Sigma-Aldrich). After incuba-
tion, cells were spinoculated (10 min, 400 rpm) and washed once
more with RPMI/20% FCS. 
In addition, we prospectively collected material from 15 healthy
subjects. Normal bone marrow (NBM, n=6) was collected from
posterior iliac crest of pediatric patients (4-18 years) undergoing
scoliosis surgery. Umbilical cord blood (CB, n=7) was obtained
after normal vaginal deliveries at full term. Mobilized peripheral
blood stem cells (mPBSC, n=2) were collected by apheresis of
adult donors pre-allotransplant. All patients or their guardians
gave their informed consent and approval was obtained by the
ethical committee, in accordance with the Declaration of Helsinki.
Buffy coats from donors were obtained from the Red Cross
(Mechelen, Belgium) and used for CTL isolation and the prepara-
tion of feeder cell medium. 
Flow cytometry analysis and cell sorting 
Cell pellets were surface stained (Online Supplementary Table S2),
followed by 20 min incubation at 4°C and washing with PBS+2%
BSA. For cell-sorting, labeled cells were resuspended in medium
and sorted on a FACSAria III with red, blue, and violet lasers (BD
Biosciences). For flow cytometry (FCM) analysis, cells were resus-
pended in PBS+2% BSA and analyzed on a LSR II or a FACSCanto
II, equipped with four or three solid-state lasers, respectively (both
BD Biosciences). All scatters were devoid of doublets based on
FSC-H/FSC-A, and propidium iodide (PI) was used to exclude
dead cells. Sorting strategies are described in Online Supplementary
Data 2.2. Regarding FCM-based cytotoxicity and cytokine assays
(Online Supplementary Data 2.9), living cells were selected using a
LIVE/DEAD staining (1:10000 dilution, ThermoFisher Scientific)
instead of PI. Target cells were stained with a Violet CellTrace™
(VT) Cell Proliferation Kit (5 mM, 1:10000 dilution, ThermoFisher
Scientific) prior to incubation with TCR-engineered CTL. After
incubation and before surface staining, Flow-Count™
Fluorospheres (1:20 diluted, Beckman Coulter) were added to each
well to enable target quantification (measurement of minimum
1000 Fluorospheres/well).
Transcript expression 
Details on micro-array profiling, RNA isolation, cDNA synthe-
sis, quantitative polymerase chain reaction (qPCR) conditions and
primers can be found in Online Supplementary Data 2.3, 2.4, 2.5 and
Online Supplementary Table S3. qPCR data analysis was performed
according to state-of-the-art methods.38,39 Relative quantity (RQ)
values were normalized against housekeeping genes GAPD,
HPRT1 and TBP. For TARP expression, normalized relative quanti-
ties were calibrated (calibrated normalized relative quantity,
CNRQ) versus a single calibrator to allow interrun comparison. For
the investigation of the subcellular localization of TARP, delta (d)
Ct between cytoplasmic and nuclear compartments were calculat-
ed and compared to MALAT1 and TBP expression. Functional
TCRG gene rearrangements were excluded if sufficient material
remained using DNA TCRG GeneScan analysis40 and/or
TRGV(J)C qPCR (Online Supplementary Table S4).
Protein detection
Details on western blotting and confocal microscopy are pro-
vided in Online Supplementary Data 2.6.
Viral transduction of acute myeloid leukemia cell lines
and generation of T-cell receptor-transgenic cytotoxic 
T cells
All transfer and helper plasmids used, and procedures for trans-
formation, plasmid isolation, transfection and transduction are
described in Online Supplementary Data 2.7 and 2.8. 
Six AML cell lines (HL-60, Kg-1a, MOLM-13, HL-60-Luc,
MOLM-13-Luc and MV4;11-Luc) were transduced with HLA-
A*0201 MHC-I encoding retrovirus, hereafter defined as A2+.
Transgenic TARP overexpression (OE) cell lines were generated
for OCI-AML3 and THP-1, next to mock controls. TARP was
knocked down in four TARP-high AML cell lines (HL-60, Kg-1a,
MV4;11 and THP-1) using three different shRNA, next to mock
controls. 
TARP-TCR engineered CTL were generated by transduction
with lentiviral (LV) or retroviral (RV) particles encoding a TCRA8-
T2A-TCRB12 sequence directed against the HLA-A*0201-restrict-
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ed synthetic TARP peptide TARP(P5L).4-13 Regarding RV 
transduced TARP-TCR CTL, mock CTL were used to correct for
non-TARP mediated lysis, and CMV-TCR transduced CTL to
evaluate aspecific killing.
Results
Discovery of T-cell receptor γ chain alternate reading
frame protein transcript expression in acute myeloid
leukemia
In order to identify LSC-specific antigens, we re-ana-
lyzed the gene set enrichment (GSE) 17054 micro-array
dataset from Majeti et al.,31 which included gene expres-
sion profiles of CD34+CD38– sorted fractions of four
healthy adults (HSC) and nine adult AML patients (LSC).
TARP ranked first amongst the top differentially expressed
genes, with all four probes in the top 20 (range log2-FC
5.13-6.92), showing a significantly higher expression in
LSC compared to HSC (P<0.01) (Online Supplementary
Figure S1). TARP had previously been identified as a trun-
cated TCR  transcript expressed in androgen-sensitive
prostate and breast adenocarcinoma (Online Supplementary
Figure S2).41,42 We further explored TARP expression in
pedAML by micro-array profiling CD34+CD38+ (n=4,
leukemic blast) and CD34+CD38– (n=3, LSC) sorted cell
populations from four pedAML patients (2 FLT3-ITD and
2 FLT3 WT) (Online Supplementary Table S1). In addition,
sorted CD34+CD38+ (n=3) and CD34+CD38- (n=2) cells
from CB were profiled to examine the expression in their
normal counterparts (Online Supplementary Figure S3).
TARP appeared to be more highly expressed in leukemic
blasts and LSC from FLT3-ITD patients compared to FLT3
WT patients and CB (Figure 1A). This finding suggested
that TARP might represent a LSC-associated target within
HR pedAML patients harboring FLT3-ITD.
To validate these data in a larger patient group, we sort-
ed CD34+CD38+ and CD34+CD38– cell populations from
nine additional pedAML (resulting in a total of 13
pedAML patients), 17 adult AML (Table 1) and 15 control
samples (n=7 CB, n=6 NBM, n=2 mPBSC). qPCR analysis
using TARP short primers (Online Supplementary Table S3
and Online Supplementary Figure S2) showed that TARP
transcripts were consistently low in HSC and myeloblasts
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Table 1. Characteristics of de novo acute myeloid leukemia (AML) patients used for sorting CD34+CD38+ and CD34+CD38– cell fractions and qual-
itative polymerase chain reaction evaluation.
                                                                              Pediatric AML (n=13)                                          Adult AML (n=17)
                                                                                  Median (Range)                                                Median (Range)
Age, years                                                                                          10 (2-16)                                                                      48 (20 - 76)
WBC count, x 109/L                                                                        66 (2.7-336)                                                                    15 (6-274)†
Morphological blast count
BM, %                                                                                              81 (34-96)                                                                     77 (28-90)†
PB, %                                                                                                 67 (1-95)                                                                       73 (7-93)||
                                                                N                                              %                                 N                                         %
Gender                                                                                                                                                                                                                           
F                                                                            7                                                      53.8%                                     9                                              52.9%
M                                                                           6                                                      46.2%                                     8                                              47.1%
Sample                                                                                                                                                                                                                            
BM                                                                        8                                                     61.5%                                   11                                            64.7%
PB                                                                         5                                                     38.5%                                    6                                             35.3%
CD34 positivity                                                    13                                                    100.0%                                   15                                             88.2%
Fusion transcript                                                 6                                                      46.2%                                    3*                                             18.8%
CBF leukemia                                                       4                                                      30.8%                                     2                                              11.8%
WT1 overexpression                                         10                                                     76.9%                                   10‡                                            71.4%
Mutation status                                                    
NPM1                                                                    0                                                       0.0%                                     5‡                                             35.7%
FLT3-ITD                                                              8                                                      61.5%                                    9†                                             60.0%
Risk classification                                                                                                            
SR                                                                         7                                                      53.8%                             Favorable                                          423.5%
HR                                                                         5                                                      38.5%                      Intermediate-I/II                                   741.2%
Unknown                                                             1                                                       7.7%                               Adverse                                           317.6%
                                                                                                                                                                               Unknown                                           317.6%
Pediatric acute myeloid leukemia (pedAML) patients were diagnosed in Belgium and treated according to the DB AML-01 (n=9, 69%) or NOPHO-DBH AML 2012 (n=4, 31%) pro-
tocol. Pediatric patients were risk stratified as previously published8 and categorized according to the French-American-British (FAB) classification into M0 (n=1), M1 (n=1), M2
(n=4), M3 (n=1), M4 (n=3), M5 (n=2), and M7 (n=1). Adult AML samples were from patients treated at the Ghent University Hospital, Ghent, Belgium (n=12, 71%) or VUmc,
Amsterdam, the Netherlands (n=5,  29%). Belgian patients were treated according to local and international guidelines, whereas Dutch patients were included in the HOVON
102 (n=3) or HOVON 132 (n=2) study.  Adults were risk stratified according to the European LeukemiaNet 2010 guidelines1 and categorized according to the FAB classification
into M1 (n=6), M2 (n=6), and M3 (n=2). WT1 overexpression was interpreted according to in-house or published cut-offs. Core binding factor (CBF)-positive leukemias comprised
AML with t(8;21)(q22;q22) (pedAML=3) and inv(16)(p13q22) (pedAML=1, adult AML=2). Other fusion transcripts detected were DEK-NUP214 (pedAML=1) and PML-RARA
(pedAML=1, adult AML=1). *One, †two,  ‡three or  ||five missing data. BM: bone marrow; F: female;  M: male; NPM1: nucleophosmin; PB: peripheral blood; WBC: white blood cell;
WT1: Wilms' tumor 1. 
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Figure 1. T-cell receptor γ chain alternate reading frame protein (TARP) transcript expression in pediatric
acute myeloid leukemia (pedAML) and adult AML leukemic cells and cell lines. For TARP qualitative poly-
merase chain reaction (qPCR), (CNRQ) values were calculated using LNCaP (prostate adenocarcinoma
cell line) as interrun calibrator. Biological replicates, e.g. cells sorted from the same patient in different
runs and independent cDNA syntheses, were depicted as independent data points. Horizontal bars indi-
cate means and error bars indicate mean±standard error or mean (SEM). Horizontal square brackets rep-
resent statistical comparisons; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. (A) TARP expression
was determined in CD34+CD38+ (n=4) and CD34+CD38– (n=3) cell fractions from four pedAML patients (2
FLT3-ITD, 2 FLT3WT) (Online Supplementary Table S1) by micro-array profiling. Sorted CD34+CD38+ (n=3)
and CD34+CD38- (n=2) cord blood (CB) cells were used as control populations.  Mean log2-FC values (y-
axis) were calculated based on both TARP probes included in the array, the x-axis represents the different
sample groups. (B) TARP expression was significantly higher in CD34+CD38– and CD34+CD38+ cell frac-
tions from AML patients (13 pedAML and 17 adult AML) compared to healthy controls (7 CB, 6 NBM and
2 mPBSC) (P<0.01, Mann Whitney U test). Blasts from NBM showed a marginally higher expression com-
pared to CB (P=0.049). (C) Comparison of TARP expression between leukemic stem cells (LSC) and blasts
within pedAML (circles, n=10) and adult AML (squares, n=12) on a per patient basis showed no significant differences (P>0.05, paired sample t-test). (D) Bars display the per-
centage of patients (%), harboring the characteristic shown in the x-axis (dichotomous variables, for details see Table 1), for TARP-high (black, n=8) and TARP-low (white, n=5)
pedAML patients. The total number of patients positive for each characteristic is shown between parentheses. Patients without central nervous system (CNS) involvement all
showed negative lumbar punctures. Data on CNS involvement and risk profile is lacking for one patient. The number of patients harboring FLT3-ITD (P<0.001) and HR profiles
(P<0.05) were significantly higher in the TARP-high group, whereas TARP-low pedAML patients included significantly more CBF-leukemia (P<0.01) and SR profiles (P<0.05) (χ2
test). (E) Differential TARP expression between LSC and blasts sorted from pediatric and adult AML patients with FLT3-ITD versus FLT3WT. A significant higher TARP expression
in LSC (P<0.01) and blasts (P<0.0001) was only detected for FLT3-ITD positive pedAML patients (Mann Whitney U test). (F) TARP expression in nine AML cell lines, five B-ALL
cell lines, the CML cell line K562, the Epstein-Barr virus (EBV)-immortalized B-cell line JY and T2 cell line, next to two breast (BT-474, MCF-7) and two prostate (LNCaP, PC3)
adenocarcinoma cell lines. Dashed lines indicate the expression observed in PC3 and LNCaP, serving as low and high reference, respectively, in agreement with previous lit-
erature.41 (G) Delta (d) Ct values were calculated for TARP, MALAT1 and TBP between cytoplasmic and nuclear compartments of THP-1 and LNCaP, in order to examine the
subcellular location of TARP. THP-1 showed a cytoplasmic residence for TARP, in agreement with LNCaP. FC: fold change; FT: fusion transcript; Kas-1: Kasumi-1; MM-6: MONO-
MAC6; mPBSC: mobilized peripheral blood stem cells; NBM: normal bone marrow. 
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sorted from CB, NBM and mPBSC (Figure 1B), although
blasts from NBM showed a marginally higher expression
compared to CB (mean CNRQ 0.12 vs. 0.045, P=0.049). In
sharp contrast, LSC and blasts from pediatric and adult
AML showed significantly (P<0.01) higher expressions
compared to their normal counterparts. Paired comparison
between LSC and blasts on a per patient basis showed no
significant differences (Figure 1C). 
A cut-off for elevated TARP expression was determined
based on the highest expression in control fractions plus
two times the standard deviation. Classification of
patients into TARP-high (8 pedAML, 13 adult AML) and
TARP-low (5 pedAML, 4 adult AML) revealed that 
FLT3-ITD (P<0.001), CNS involvement and HR profile
(P<0.05) were exclusively present in TARP-high pedAML
patients (Figure 1D). TARP expression was shown to be
significantly higher in sorted LSC (P<0.01) and blasts
(P<0.0001) from FLT3-ITD compared to FLT3 WT
pedAML (Figure 2E). In adult AML, high TARP expression
was not restricted to FLT3-ITD. On the other hand, all
pediatric (Figure 1D) and adult (Online Supplementary
Figure S4A) core-binding factor (CBF) leukemia were clas-
sified as TARP-low patients (P<0.01). TARP-low pedAML
patients were included in the standard risk (SR) groups
(P<0.05). No significant differences in age, white blood
cell (WBC) count, or blast percentages were observed
between TARP-high and -low pediatric or adult AML
patients (Online Supplementary Figure S4B and C). We thus
conclude that TARP is highly and specifically expressed in
AML leukemic cells from both adults and children, show-
ing a significant association with FLT3-ITD in pedAML.
Next, we evaluated TARP transcript levels in cell lines of
various origin. Expression in breast and prostate adenocar-
cinoma (PC3, BT-474, LNCaP and MCF-7) was in agree-
ment with previous findings42 (Figure 1F). No expression
was detected in five B-ALL cell lines, CML cell line K562,
EBV-immortalized B-cell line JY and T2 cell line.
Expression in AML cell lines, on the other hand, was sig-
nificantly increased (P<0.001, one-way ANOVA). The
highest expression was observed in HL-60, HNT-34, Kg-
1a, MV4;11 and THP-1 (median CNRQ 1.12, range 0.75-
4.84), whereas low transcript levels were observed in Kas-
1, MOLM-13, MONO-MAC6 and OCI-AML3 (median
CNRQ 0.080, range 0.049-0.22). Furthermore, fractiona-
tion revealed a mainly cytoplasmic localization of TARP
mRNA in THP-1 (Figure 1G), as previously shown in
LNCaP43. 
To evaluate whether the TARP transcript detected in
AML is identical to previous reports, we sequenced the
TRGC region of different TARP amplicons obtained by
qPCR for AML cell lines and pedAML leukemic cells.
Using TARP long primers, we observed a single band for
B. Depreter et al.
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Figure 2.  T-cell receptor γ chain alternate reading frame protein (TARP) expression in cell lines evaluated by western blotting. Whole-blot images with ladders used
for size estimation are shown in Online Supplementary Figure S7. (A) TARP transgenic (OE) cell lines generated for OCI-AML3 and THP-1 showed a 27 kDa protein
for GFP and a 15-25 kDa protein for TARP. In agreement with low TARP transcript levels, the OCI-AML3 mock cell line only showed a 27 kDa GFP protein. TARP expres-
sion in THP-1 OE was higher than OCI-AML3 OE, most likely resulting from both transgenic and cognate TARP protein expression, since THP-1 was categorized by
qualitative polymerase chain reaction (qPCR) as a TARP-high acute myeloid leukemia (AML) cell line. (B) Immunoblotting of TARP and β-actin in AML cell lines (HL-
60, Kg-1a, MOLM-13, OCI-AML3, MV4;11 and THP-1) next to LNCaP. Protein expression mostly matched transcript levels, except for Kg-1a, although confocal
microscopy did allow TARP protein staining in Kg-1a. β-actin expression appeared to be lower for LNCaP and MOLM-13, although equal amounts of protein were
loaded.  (C) Immunoblotting of TARP and β-actin in selected shRNA-mediated knockdown (KD) AML cell lines for MV4;11, HL-60 and THP-1, next to their respective
mock and wild-type (WT) cell line. For HL-60, a stable knockdown was introduced by shRNA 3 (19.4% compared to mock). KD: knockdown; OE: overexpression. 
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Kg-1a, which was similar to the LNCaP and TRGC1 refer-
ence sequence (Online Supplementary Figure S5A).
Unexpectedly, three fragments were observed in the sort-
ed blasts and LSC from TARP-high pedAML patients and
the MV4;11 cell line. Cloning and sequencing of each frag-
ment (Online Supplementary Figure S5B) revealed that the
largest fragments were artificial heteroduplexes,44 whereas
the smallest fragments were identical to the fragments
from Kg-1a and LNCaP. Medium-sized fragments were
consistently 48 bp longer, and showed the same size as
the HSB-2 amplicon, a T-cell acute lymphoblastic
leukemia (T-ALL) cell line with functional TRGC2
rearrangements.45 As TRGC2 contains a duplicated second
exon (48 bp) compared to TRGC145 (Online Supplementary
Figure S2), we hypothesized that there might be an alter-
native TARP transcript in AML. Indeed, most AML cell
lines, but none of the prostate and breast adenocarcinoma
cell lines, showed TRGC1 as well as TRGC2 amplicons
(Online Supplementary Figure S5C and E). Single bands for
exon 3 and exon 1 amplicons in all cell lines provided evi-
dence that the occurrence of the second transcript is relat-
ed to the TRGC2 duplicated second exon. Altogether,
TARP was highly expressed in approximately half of the
AML cell lines evaluated, and both TRGC1- and TRGC2-
related transcripts co-existed in AML.
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Figure 3. T-cell receptor γ chain alternate reading frame protein (TARP) protein detection in Kg-1a and patient leukemic cells by confocal microscopy. Merged pat-
terns visualize TARP (red) and HSP-60 (top lane) or calnexin (bottom lane) (both in green) co-localization (yellow fusion signals) together with DAPI nuclear counter-
staining (blue). Leukemic cells were sorted from two pediatric acute myeloid leukemia (pedAML) patients, classified as TARP-high and TARP-low by qualitative poly-
merase chain reaction. Calnexin staining was not performed on primary cells due to lack of material. Within Kg-1a and the sorted TARP-high leukemic cells, TARP
expression was enriched at the cells’ protrusions, indicated by arrows.
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Figure 4. Functional evaluation of T-cell receptor (TCR)-transgenic cytotoxic T cells (CTL) towards cognate and modified cell lines and patient leukemic cells. (A)
Cytokine response (IFN-γ/IL-2 expression within the CD3+/CD8+ compartment) by co-incubation (1 hour, h) with OCI-AML3 and THP-1 was evaluated by both lentiviral
(LV) and retroviral (RV) TCR-T-cell receptor γ chain alternate reading frame protein (TARP) CTL. LNCaP and patient leukemic cells (single experiment) were only eval-
uated by LV transduced TARP-TCR CTL. For each target, positive (+) or negative (-) HLA-A*0201 and TARP expression, in this respective order, is indicated between
brackets. HLA-A*0201 and TARP co-expressing cell lines (LNCaP and THP-1) were unable to trigger higher cytokine release than OCI-AML3 with low TARP expression.
Leukemic cells from a TARP-high pediatric acute myeloid leukemia (pedAML) patient triggered a 2-fold higher cytokine release compared to a TARP-low pedAML
patient.  (B) Lytic response of LV and RV TARP-TCR CTL versus HLA-A*0201-positive TARP-high (black symbols) and TARP-low (white symbols) targets, measured by
a chromium51 release assay after 4 h. Highest lysis of TARP-high cell lines was observed at E/T ratio 50/1 for LV and 10/1 for RV TARP-TCR CTL (percentages indicated
between brackets), whereas OCI-AML3 (HLA-A*0201+, TARP–) remained unaffected. (C) Lytic response of LV and RV TARP-TCR CTL versus towards wild-type (WT),
transgenic and pulsed AML cell lines, measured by a 48-h FCM-based cytotoxicity assay. The dashed line indicates the highest level of non-TARP mediated back-
ground killing observed for LV TARP-TCR CTL, as no mock CTL could be constructed. Positive (+) or negative (-) expression for HLA-A*0201 and TARP is shown, in this
respective order, between brackets. Bold symbols indicate the expression differing from wild-type, either by retroviral transduction or pulsing. HLA-A*0201 transgenic
AML cell lines were more efficiently lysed compared to their HLA-A*0201-negative counterparts (Kg-1a, MOLM-13, HL-60). Higher lysis was observed for transgenic
TARP OE or peptide-pulsed cell lines compared to the WT cell line (OCI-AML3, THP-1), except for killing of TARP OE OCI-AML3 cell line by RV TARP-TCR CTL. (D) Lysis
by LV TARP-TCR CTL, measured at different time points (8h, 24h, 48h and 56h, as indicated on x-axis), based on the luminescence release by transgenic HLA-A*0201-
expressing TARP-high AML cell lines with respect to the HLA-A*0201 WT cell line  (HL-60-Luc, MOLM-13-Luc and MV4;11-Luc: black symbols). In addition, lysis of the
TARP-low, cognate HLA-A*0201-positive OCI-AML3 cell line was evaluated (white symbols). Mean lysis (%) observed after 48 h is indicated next to whiskers, repre-
senting the mean±standard error of mean. (E) 48-h FCM-based cytotoxicity assay evaluating lysis of primary leukemic cells (adult AML=5, all FLT3-ITD mutated) by
LV TARP-TCR transduced CTL (biological duplicates). TARP transcript expression (CNRQ) is shown in the x-axis for each target.  IFN-γ: interferon gamma; IL-2: inter-
leukin-2; INF: influenza.
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T-cell receptor γ chain alternate reading frame protein
is expressed in acute myeloid leukemia cell lines and
patient leukemic cells
We generated TARP transgenic cell lines in order to opti-
mize western blot experiments and evaluate TARP protein
expression in AML. THP-1 and OCI-AML3 OE cell lines
showed a significant higher TARP transcript expression
(P<0.01) compared to mock controls (Online Supplementary
Figure S6A). Western blotting confirmed presence of TARP
and GFP proteins in both OE cell lines, with a size of
around 20 kDa and 27 kDa, respectively (Figure 2A and
Online Supplementary Figure S7). Concordantly, the OCI-
AML3 mock cell line, negative for TARP, only showed a 27
kDa GFP protein. WT AML cell lines HL-60, MV4;11,
THP-1 and MOLM-13, as well as LNCaP, also showed a
20 kDa TARP protein, with expression corresponding to
the transcript levels (Figure 2B and Online Supplementary
Figure S7). TARP knockdown (KD) cell lines were generat-
ed for HL-60, Kg-1a, MV4;11 and THP-1 using TARP-tar-
geting shRNA, next to mock controls. Transcript levels
were efficiently down-regulated (Online Supplementary
Figure S8), and KD cell lines for HL-60, MV4;11 and THP-
1 showing the highest transcript downregulation were
selected for western blotting (Figure 2C and Online
Supplementary Figure S7). Protein levels were efficiently
down-regulated in HL-60 transduced with shRNA 3
(19.4% compared to mock). This downregulation was less
clear in MV4;11 and THP-1: 116% (shRNA 3) and 108%
(shRNA 3) versus 63% (shRNA 2), respectively. 
To confirm western blot data and determine the subcel-
lular location of TARP, confocal microscopy was per-
formed using TARP antibodies combined with mitochon-
drial (HSP-60) and endoplasmic reticulum (ER, calnexin)
staining. The over-expressing OCI-AML3 and THP-1 cell
lines (Online Supplementary Figure S6B and C) and TARP-
high WT AML cell lines showed a perinuclear membra-
nous-type TARP staining pattern (Kg-1a (Figure 3), HL-60,
MV4;11 and THP-1 (Online Supplementary Figure S9). This
finding was in contrast to the barrel-shaped TARP pattern
with mitochondrial co-localization reported in LNCaP.43
Co-localization with calnexin, presenting as a speckled
pattern throughout the ER, was more abundant in some
cell lines, e.g. Kg-1a, showing TARP enrichment at the
cells’ protrusions. TARP-low cell lines concordantly
showed weak or negative TARP protein staining (Online
Supplementary Figure S8). Importantly, the leukemic cells
sorted from a TARP-high and TARP-low pedAML patient
also illustrated differential TARP protein expression in
agreement with the transcript levels, again showing limit-
ed mitochondrial overlap (Figure 3).
T-cell receptor γ chain alternate reading frame protein
transgenic cytotoxic T cells display specific 
anti-leukemic activity 
To explore if TARP might represent an immunothera-
peutic target in AML, we evaluated the cytokine and cyto-
toxicity response of TARP-TCR transgenic CTL, encoding
a previously developed TCRA8-T2A-TCRB12 sequence
targeting the HLA-A2 enhanced affinity TARP(P5L)4-13 epi-
tope.46,47 As concomitant HLA-A*0201 and TARP expres-
sion is required to trigger TCR-mediated killing, 
HLA-A*0201 transgenic cell lines were generated for 3 WT
cell lines (HL-60, Kg-1a and MOLM-13) and 3 Luc-positive
cell lines (HL-60-Luc, MOLM-13-Luc, MV4;11-Luc). 
First, target specificity of the TARP-TCR was examined
in a non-competitive environment using T2 cells (endoge-
nous HLA-A*0201+) pulsed with exogenous peptides
(Online Supplementary Table S3). As expected, we found
stronger cytokine responses (Online Supplementary Figure
S10A) and higher killing rates (Online Supplementary Figure
S10B and C) towards the TARP(P5L)4-13 than to the cognate
TARP4-13 peptide for both RV and LV transduced CTL, with
LV TARP-TCR CTL generally reacting stronger. T2 cells
pulsed with non-TARP-related peptides (INF, CMV) were
not affected, although CMV-pulsed T2 cells were effi-
ciently recognized by CMV-TCR CTL, indicating a high
specificity of the TARP-TCR.
Second, we explored the immunogenicity of cell lines
with endogenous HLA-A*0201 presentation. Exposure to
LNCaP and THP-1 appeared to be insufficient to trigger
cytokine release for both LV and RV transduced TARP-
TCR CTL (Figure 4A). Using a chromium51 release assay,
we observed a lytic response by LV transduced TARP-TCR
CTL starting from effector to target ratio (E/T) 10/1, with
a maximal average response at 50/1 (LNCaP 10%, THP-1
24%), whereas RV transduced TARP-TCR CTL performed
best at 10/1 (THP-1 12%) (Figure 4B). The TARP-low AML
cell line OCI-AML3 remained unaffected under all condi-
tions. Altogether, as the TARP-TCR targets the enhanced
HLA-A2 TARP(P5L)4-13 binding peptide, we observed
weaker responses against endogenous TARP-expressing
cell lines compared to pulsed T2 cells. 
Third, lysis of TARP-high HLA-A*0201-negative cell
lines was evaluated versus their HLA-A*0201 transgenic
counterparts in a 48-h FCM-cytotoxicity assay. In addi-
tion, killing of TARP transgenic or TARP-pulsed HLA-
A*0201-positive cell lines was compared to the respective
TARP-low WT cell line (Figure 4C). A non-TARP mediated
lysis by LV TARP-TCR CTL of maximal 20% was
observed (indicated by dashed line). Stable transduction of
HLA-A*0201 increased killing for Kg-1a compared to the
WT cell line (29% vs. 13%), whereas killing of MOLM-13,
with lower TARP expression levels, remained unaffected
when HLA-A*0201 was introduced. Transgenic TARP OE
and TARP(P5L)4-13 pulsed OCI-AML3 cells were prone to a
higher lysis than the WT cell line (44% and 55%, respec-
tively, vs. 24%). Killing of TARP OE/pulsed THP-1 cells
was only marginally up-regulated, most likely due to an
already high endogenous expression. These data were
confirmed using RV TARP-TCR CTL, and corrected for
non-TARP mediated lysis using mock CTL. HLA-A*0201
expression again increased killing of Kg-1a (46% vs. -4%)
and HL-60 (40%  vs. 15%) compared to the WT cell line.
Up-regulated killing of transgenic TARP OE THP-1 cells
was again limited. For OCI-AML3, lysis was up-regulated
after pulsing, but remained low for the TARP OE trans-
genic cell line. Killing by LV TARP-TCR CTL was addi-
tionally evaluated in a bioluminescence imaging (BLI)-
based assay using Luc-positive AML cell lines with high
TARP expression (HL-60 and MV4;11) and low TARP
expression (MOLM-13 and OCI-AML3) (Figure 4D). A
higher lysis was observed for HL-60-Luc and MV4;11-Luc
when expressing HLA-A*0201 at 48 h and 56 h, indicating
that also in long-term cytotoxicity experiments HLA-
A*0201 restricted TARP-specific killing could be detected.  
Finally, we explored the feasibility of therapeutic target-
ing of primary leukemic cells by LV TARP-TCR CTL. Co-
incubation with blasts sorted from a TARP-high pedAML
patient resulted into a 2-fold higher IFN-γ  and IL-2 pro-
duction compared to a TARP-low pedAML patient (22%
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vs. 10%) (Figure 4A). Moreover, TARP-TCR CTL were
also capable of killing leukemic cells from de novo adult
AML patients (n=5) (Figure 4E). Lysis ranged between
12% and 68%, and borderline correlated to TARP tran-
script levels (Spearman's coefficient 0.82, P=0.089).
Discussion 
We demonstrated increased TARP expression in AML
LSC (CD34+CD38–) and blasts (CD34+CD38+) from pri-
mary patients compared to their normal counterparts as
well as AML cell lines. We also showed that TARP protein
is expressed in primary AML leukemic cells and are ade-
quately presented on HLA molecules, which makes the
cells targetable for immunotherapy. 
TARP expression has only been investigated in prostate
tissue and androgen-sensitive prostate adenocarcinoma
and breast adenocarcinoma,42,43,48 next to a single report on
salivary adenoid cystic carcinoma.49 We found that TARP
expression was significantly (P<0.001) higher  in FLT3-
ITD compared to FLT3WT pedAML patients at diagnosis,
whereas no significant difference was observed in adult
AML. Importantly, enormous differences in the genomic
landscape in adult compared to pedAML were shown,50,51
potentially explaining some of the differential associations
observed in our cohorts. The association between TARP
expression and a poor prognosis is in agreement with a
recent report, investigating the association between tran-
script expression and clinical outcome in pedAML, rank-
ing TARP within the top genes significantly associated
with a detrimental outcome.52 To shed light on the link
between FLT3-ITD and TARP, mRNA sequencing of the
transgenic OE and KD cell lines compared to their WT cell
line is ongoing. As it was recently shown that the 
FLT3-ITD regions encode immunogenic, HLA-presented
neo-epitopes,53 the benefit of CTL therapy targeting both
leukemogenic molecules in pedAML could be of great
interest. On the other hand, CBF leukemias, representing
a favorable cytogenetic subgroup,2,8 were only present
(P<0.01) in the TARP-low group for both pediatric and
adult patients. AML cell lines derived from pediatric cases
(MV4;11, THP-1) and LSC-enriched cell lines (Kg-1a,
HNT-34), showed the highest TARP levels, confirming a
relation between TARP, the LSC compartment and
pedAML, although also HL-60 (adult, CD34–) showed
high expression. Whether TARP remains differentially
expressed within LSC outside the predominant
CD34+CD38– compartment, as it does within CD34–
AML,15,54 needs to be explored further. In addition, we
showed that transcripts differ from those in solid tumors
and are derived from both the TRGC1 and TRGC2 coding
regions. Sequencing analysis indicated the presence of a
second, AML-exclusive, TARP transcript encoding TRGC2
instead of TRGC1.
TARP protein expression was in agreement with tran-
script levels, showing a 15-25 kDa fragment in AML cell
lines. In breast and prostate adenocarcinoma, TARP had
previously been defined as a 7 kDa protein,42,48 although
also a 9 kDa fragment was reported in MCF-7.42,48
Fritzsche et al. detected protein sizes in prostate carcino-
ma of 20-25 kDa,55 comparable to our findings, whereas
Yue et al. reported a 15 kDa protein.49 Besides its size, the
subcellular localization of TARP in AML needs to be
refined. qPCR analysis revealed cytoplasmic localization,
and confocal microscopy showed sporadic ER overlap, in
contrast to previously reported mitochondrial co-localiza-
tion.43 We observed an enrichment of TARP at the cells’
protrusions in Kg-1a and sorted leukemic cells.
Protrusions are kinetic cytoskeletal abnormalities formed
during chemokine-induced cell migration, e.g. homing of
CD34+ HSC towards the bone marrow niche.56 The pres-
ence of molecular abnormalities in CD34+ progenitor cells
was shown to increase protrusion formation.57 Indeed,
LSC were reported to compete with HSC for endosteal
niche engraftment, where they are protected from
chemotherapy-induced apoptosis.12,58 Whether TARP
interferes in homing and chemoprotection of leukemic
AML cells in the BM microenvironment needs to be elu-
cidated. Although protein expression was readily up-reg-
ulated in TARP transgenic cell lines, shRNA-mediated
knockdown appeared to be less efficient. Possible expla-
nations are the presence of escape mechanisms and alter-
native translation pathways during silencing or a very
high stability of the TARP protein, persisting in the cell
for a long period of time. 
To explore TARP as an immunotherapeutic target in
AML, we evaluated the cytokine release and cytotoxic
killing capacities of TARP-TCR transgenic CTL in vitro.
TARP and HLA-A*0201 co-expressing cell lines were effi-
ciently lysed, and although evaluated on a limited number
of patients (n=5), TARP-TCR CTL were able to kill pri-
mary leukemic cells with a borderline correlation to the
TARP transcript expression. Interestingly, weaker respons-
es were observed for the cognate TARP4-13 peptide, since
the TCR is directed against the HLA-A*0201 enhanced
affinity TARP(P5L)4-13 peptide. Moreover, pulsed T2 cells
appeared to be more susceptible than AML cells. This
finding is in agreement with previous data,47,59 and several
reasons may account for this phenomenon. First, peptide
processing, transport and/or MHC-I presentation may be
disturbed in leukemic cells.60 Second, high and stable HLA-
A*0201 expression is vital for triggering lytic responses,
and transgenic expression might diminish during culture.
Therefore, we cannot exclude the possibility that HLA-
A*0201-mediated TARP presentation within the trans-
genic OCI-AML3 cell line had diminished during long-
term culture. Third, competition between transgenic and
endogenous MHC-I molecules might block HLA-A*0201-
guided peptide presentation. Indeed, the TARP-TCR was
shown to suffer from low MHC-I avidity compared to for-
eign epitope-directed TCR.61 Cloning the TARP4-13-TCR
sequence into a retroviral construct enabled higher trans-
duction efficiencies and the generation of mock CTL to
correct non-TARP mediated lysis, which are lacking in
previous reports.37,49 As promoters driving TCR expression
differed between constructs, and functional activity is
known to correlate with TCR cell-surface expression,62 it
was no surprised that different killing rates between LV
and RV transduced CTL were osberved. In addition,
intrinsic reactivity, HLA status and endogenous TCR
repertoire of each donor as such might have an impact.62
In addition, comparing reactivity by effectors from an allo-
geneic versus autologous setting will be implemented in
future experiments. 
In conclusion, we showed that TARP is highly expressed
in AML leukemic cells, including the CD34+CD38– LSC
compartment, while absent in normal counterparts.
Moreover, TARP expression was associated with 
FLT3-ITD in pedAML. We provide in vitro evidence that
B. Depreter et al.
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TARP-directed CTL effectively kill TARP and HLA-
A*0201 co-expressing cell lines and primary leukemic
cells, and thus hold great promise for immunotherapeutic
T-cell therapy.
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